R
RQ Bio develops cell therapy manufacturing technology for biotech and pharma companies.
$108.6MSeries A
Investor undisclosed
A $108M Series A for manufacturing tech (not the therapy itself) signals that cell therapy scaling has moved from R&D bottleneck to commercialization bottleneck—investors are betting the hard part now is making it at volume, not inventing it. If you're building biotech infrastructure, this validates that the market will pay for solutions that compress manufacturing timelines and costs, not just efficacy gains.